Ersilia is a nonprofit enterprise that aims to provide the community with a set of computational tools related to global health drug discovery. Our goal is to lower the barrier to the development of new medicines by setting up an environment for open-source drug discovery. In Ersilia, we build and deploy thousands of predictive models related to target profiling, drug repurposing and safety, with a special emphasis on neglected tropical diseases.

Open-source drug discovery for global health

Researchers interested in a specific disease, target or pathogen can use our models to prioritize drug candidates. The way around is also true. Given a compound of interest, Ersilia will scope for potential mechanisms of action, side effects and indications.

Open Source

Our goal is to democratize drug discovery by providing a user-friendly, transparent resource available to everyone.

Global Reach

We empower research where medical care is most needed by fostering collaborations with health organizations in low and middle-income countries.

Predictive Models

We illuminate neglected regions of the chemical space to enable drug repurposing, hit-to-lead optimisation and generation of new molecules.

Ersilia technology is data-driven and achieves state-of-the-art performance through the integration of chemical, genomic and biomedical text data. Our predictive models are trained on millions of data points collected from the scientific literature and are available at no cost under a Creative Commons licence.

Unlike conventional structure-activity relationship models, Ersilia capitalizes on bioactivity signatures, a richer representation of compounds recently developed by one of our co-founders. Bioactivity signatures embed the biological characteristics of small molecules, including their targets and side-effects profiles, and are thus more powerful and clinically relevant predictors of bioactivity.

Our team merges expertise in chemistry, molecular biology and computational pharmacology with a natural enthusiasm for global health. We truly believe in open source science as a means to generate low revenue drugs and thus contribute to a more egalitarian world.

Edoardo Gaude
CEO and co-founder

Edoardo is motivated in making an impact by applying his expertise to real-world medical needs. After a PhD in oncology at the University of Cambridge, Edoardo took on a clinical scientist position at Owlstone Medical Ltd (Cambridge, UK). In 2018, he founded POCKiT diagnostics Ltd, a medical company aimed at improving stroke care. During his academic and industrial career, he published ~40 scientific articles, filed 3 patents, designed and performed several clinical studies, and contributed to raising £1.2M public and private funds. With Ersilia, Edoardo aims to harness his science entrepreneurship expertise for the creation and furthering of open innovation and science crowdsourcing. He is extremely excited to witness how this approach will transform the drug discovery field.

Learn more

Miquel Duran
CSO and co-founder

Miquel’s research interests lay at the intersection between drug discovery and large-scale biological data analysis. During his PhD studies and early career, Miquel developed state-of-the-art in silico methods, producing over 25 scientific publications in a broad range of topics, from theoretical chemistry to phenotypic screening. Along this process, he has worked at IRB Barcelona, the Massachusetts Institute of Technology (MIT), Tel Aviv University, ISGlobal-CISM (Mozambique) and CIDRZ (Zambia). With Ersilia, Miquel aims to apply his expertise to the context of open science and global health, accelerating the discovery of treatments for neglected clinical needs.

Learn more

Gemma Turon
Project manager

Trained as a molecular biologist, Gemma completed a PhD in colorectal cancer and stem cells at IRB Barcelona. Her interests, though, span a broad range of topics, with a special interest in global health and neglected diseases. This led her to move, recently, to Zambia and Palestine, to cooperate with local social circus NGOs, her other passion. These stays have given her insight on how to work and implement programs in emerging economies. With Ersilia, Gemma hopes to bring together her scientific knowledge and her social work to deliver high-quality, fast services that will effectively tackle some of the most urgent health issues in developing countries.

Learn more